Subscribe to RSS
Inhaled Corticosteroid Exposure in Hospitalized Infants with Bronchopulmonary DysplasiaFunding R.J.M. and E.K. receive support from the Office of the Director of the National Institutes of Health under award UG1OD024953. The remaining authors did not receive funding.
Objective The objective of this paper was to determine inhaled corticosteroid (IC) use in infants with bronchopulmonary dysplasia (BPD), define the interhospital variation of IC administration to infants with BPD, and compare clinical, demographic, and hospital factors associated with IC use.
Study Design Using the Pediatric Health Information System database, a retrospective multicenter cohort of 4,551 infants born at <32 weeks of gestation with developing BPD was studied. The clinical, demographic, and hospital characteristics of infants exposed and not exposed to ICs were compared.
Results IC use varied markedly between hospitals, ranging from 0 to 66% of infants with BPD exposed to ICs. Increased annual BPD census was not associated with IC use. In total, 25% (1,144 out of 4,551) of patients with BPD and 43% (536 out of 1,244) of those with severe BPD received ICs. Increased IC exposure was associated with lower birth weight and gestational age, days on respiratory support, need for positive pressure ventilation at 36-week postmenstrual age, need for tracheostomy, and increased use of systemic steroids, bronchodilators, and diuretics.
Conclusion IC exposure is common in infants with BPD, with substantial interhospital variability. IC use was associated with more severe disease. Hospital experience did not account for the wide variability in IC use by the hospital. Further research into the effects of ICs use is urgently needed to help guide their use in this vulnerable population.
The risks and benefits of IC use in infants with BPD are incompletely understood.
IC use is common in infants with BPD (25%) and severe BPD (43%) varies widely by hospital (0–66% of patients with BPD received an IC).
Hospital experience did not account for the wide interhospital variation in IC use.
Keywordsbronchopulmonary dysplasia - inhaled corticosteroids - budesonide - beclomethasone - fluticasone
Received: 15 December 2021
Accepted: 28 April 2022
Accepted Manuscript online:
06 May 2022
Article published online:
07 June 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 Higgins RD, Jobe AH, Koso-Thomas M. et al. Bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 2018; 197: 300-308
- 2 Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth Defects Res A Clin Mol Teratol 2014; 100 (03) 145-157
- 3 Nelin LD, Logan JW. The use of inhaled corticosteroids in chronically ventilated preterm infants. Semin Fetal Neonatal Med 2017; 22 (05) 296-301
- 4 Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2016; 138 (06) e20162511
- 5 Guaman MC, Gien J, Baker CD, Zhang H, Austin ED, Collaco JM. Point prevalence, clinical characteristics, and treatment variation for infants with severe bronchopulmonary dysplasia. Am J Perinatol 2015; 32 (10) 960-967
- 6 Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 2006; 117 (06) 1979-1987
- 7 Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin Jr DK, Smith PB. Best Pharmaceuticals for Children Act—Pediatric Trials Network. Medication use in the neonatal intensive care unit. Am J Perinatol 2014; 31 (09) 811-821
- 8 Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Utilization of inhaled corticosteroids for infants with bronchopulmonary dysplasia. PLoS One 2014; 9 (09) e106838
- 9 Greenberg JM, Poindexter BB, Shaw PA. et al. Respiratory medication use in extremely premature (<29 weeks) infants during initial NICU hospitalization: results from the prematurity and respiratory outcomes program. Pediatr Pulmonol 2020; 55 (02) 360-368
- 10 Ryan RM, Keller RL, Poindexter BB. et al; PROP Investigators. Respiratory medications in infants <29 weeks during the first year postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. J Pediatr 2019; 208: 148-155.e3
- 11 Euteneuer JC, Kerns E, Leiting C, McCulloh RJ, Peeples ES. Inhaled bronchodilator exposure in the management of bronchopulmonary dysplasia in hospitalized infants. J Perinatol 2021; 41 (01) 53-61
- 12 Htun ZT, Schulz EV, Desai RK. et al. Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia. J Perinatol 2021; 41 (08) 1783-1796
- 13 Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2017; 10: CD002058
- 14 Stark AR, Carlo WA, Tyson JE. et al; National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. N Engl J Med 2001; 344 (02) 95-101
- 15 Williams DM. Clinical pharmacology of corticosteroids. Respir Care 2018; 63 (06) 655-670
- 16 Ng PC, Fok TF, Wong GW. et al. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 1998; 83 (07) 2390-2393
- 17 Cole CH, Shah B, Abbasi S. et al. Adrenal function in premature infants during inhaled beclomethasone therapy. J Pediatr 1999; 135 (01) 65-70
- 18 Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC. CAMP Research Group. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics 2008; 122 (01) e53-e61
- 19 Kelly HW, Sternberg AL, Lescher R. et al; CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367 (10) 904-912
- 20 Bassler D, Shinwell ES, Hallman M. et al; Neonatal European Study of Inhaled Steroids Trial Group. Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. N Engl J Med 2018; 378 (02) 148-157
- 21 Bassler D, Plavka R, Shinwell ES. et al; NEUROSIS Trial Group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med 2015; 373 (16) 1497-1506
- 22 Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol 2017; 52 (07) 968-975
- 23 Yeh TF, Chen CM, Wu SY. et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med 2016; 193 (01) 86-95